Online Only Articles

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients

Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Vol. 105 No. 1 (2020): January, 2020 https://doi.org/10.3324/haematol.2019.219683